<DOC>
	<DOC>NCT02306291</DOC>
	<brief_summary>This study will evaluate GMI-1271, a specific E-selectin antagonist, in acute myeloid leukemia in combination with standard agents used to treat this disease.</brief_summary>
	<brief_title>Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>Inclusion criteria: 1. AML (including secondary AML) diagnosed as per WHO criteria 2. For relapsed/refractory subjects only: Subjects age ≥ 18 years with relapsed or refractory AML after ≤ 2 prior induction regimens, at least one containing anthracyclines Medically eligible to receive MEC Absolute blast count (ABC) ≤ 40,000/mm 3. For treatmentnaïve subjects only: Subjects ≥ 60 years of age with newly diagnosed AML Medically eligible to receive "7+3" cytarabine/idarubicin ABC count ≤ 40,000/mm 4. ECOG performance status 02 5. Hemodynamically stable and adequate organ function Exclusion criteria: 1. Acute promyelocytic leukemia 2. Acute leukemia of ambiguous lineage (biphenotypic leukemia) 3. Active signs or symptoms of CNS involvement by malignancy 4. No prior GCSF, GMCSF or plerixafor within 14 days of study drug dosing 5. Known history or evidence of active hepatitis A, B, or C or HIV 6. Uncontrolled acute life threatening bacterial, viral or fungal infection 7. Active graft versus host disease (GVHD) ≥ Grade 2 or extensive chronic GVHD requiring immunosuppressive therapy 8. Hematopoietic stem cell transplantation ≤ 4 months of dosing 9. Clinically significant cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>E-selectin</keyword>
	<keyword>relapse refractory</keyword>
	<keyword>elderly newly diagnosed</keyword>
	<keyword>induction</keyword>
</DOC>